Genome-wide association study of virologic response with efavirenz-containing or abacavir-containing regimens in AIDS clinical trials group protocols.

There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

Abstract

Efavirenz and abacavir are components of recommended first-line regimens for HIV-1 infection. We used genome-wide genotyping and clinical data to explore genetic associations with virologic failure among patients randomized to efavirenz-containing or abacavir-containing regimens in AIDS Clinical Trials Group (ACTG) protocols.

Related collections

Author and article information

Journal

Journal ID (iso-abbrev): Pharmacogenet. Genomics

Title: Pharmacogenetics and genomics

ISSN (Electronic): 1744-6880

ISSN (Print): 1744-6872

Publication date (Electronic): Feb 2015

Volume: 25

Issue: 2

Affiliations

[1 ] aBrandeis University, Waltham bCenter for Biostatistics in AIDS Research, Harvard School of Public Health cDepartment of Medicine, Harvard Medical School, Boston, Massachusetts dLos Angeles Biomed Research Institute at Harbor-UCLA Medical Center, Torrance eDepartment of Medicine and Center for AIDS Research, University of California San Diego, San Diego, California fWeill Cornell Medical College, New York, New York gDepartment of Medicine, Vanderbilt University School of Medicine, Nashville, Tennessee, USA hDepartments of Medical Genetics and Epidemiology, University Medical Center Utrecht, Utrecht, The Netherlands iSchool of Life Sciences, The Swiss Institute of Technology jInstitute of Microbiology University Hospital, University of Lausanne, Lausanne, Switzerland.

Article

Mid ID: NIHMS668995

DOI: 10.1097/FPC.0000000000000106

PubMed ID: 25461247

SO-VID: 7e9fa27f-111d-4064-bad7-13ea018e2828

History

Data availability:

Comments

Comment on this article

scite_

Cited by 5

See all cited by